Allogene Q2 Loss Narrows; Cash Runway Extended to Q1 2029
ALLO has more than doubled off its 52-week low of $0.99.
Summary
Allogene's Q2 loss narrowed and its cash runway now extends into 2029, backed by recent equity raises.
Key Events · Earnings and Guidance · ALLO
-
Q2 Loss Narrows
Net loss of $42.7M for Q2 2026, down from $50.9M in Q2 2025, driven by lower R&D spending.
-
Cash Runway Extended
Cash, cash equivalents and investments of $423.6M as of June 30, 2026, expected to fund operations into Q1 2029.
-
Recent Equity Raises
April 2026 public offering raised $187.9M net; ATM sales added $20.7M net during H1 2026.
-
Authorized Shares Doubled
Stockholders approved increasing authorized common stock from 400M to 800M shares on June 18, 2026.
Analysis · ALLO · Life Sciences
Allogene reported a Q2 net loss of $42.7M, down from $50.9M a year ago, and ended the quarter with $423.6M in cash and investments. The company says that's enough to fund operations into the first quarter of 2029, removing near-term financing risk. The quarter also included a $187.9M public offering and a $20.7M ATM raise, which diluted shareholders but strengthened the balance sheet.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ALLO was trading at $2.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $714.5M. The 52-week trading range was $0.99 to $4.46. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.